Product Information
VENLAFAXINE HCL ER 150 MG CAP is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.1190 per EA under NDC 31722000490. Its NADAC has been published 308 times since Nov 11, 2020.
FDA first approved this application on Jul 8, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722000490
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212277FDA Approved
7/8/2019
TE Code
AB
On Market Since
7/8/2019
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 150 MG CAP has been published 308 times since Nov 11, 2020, and over the history we have for it it has declined 36.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1190 per EA |
|---|---|
| All-time high | $0.2086 (Aug 11, 2021) |
| All-time low | $0.1057 (Nov 20, 2024) |
| 52-week high | $0.1309 |
| 52-week low | $0.1152 |
| Median price | $0.1482 |
| Average price | $0.1484 |
| Largest weekly change | +21.6% (Aug 21, 2024) |
| Weeks tracked | 308 |
| Tracking since | Nov 11, 2020 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Venlafaxine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 150 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 150 MG CAP, manufactured by Camber Pharmaceuticals Inc., is $0.1190 per EA (NDC 31722000490), effective Sep 30, 2026.
How has the price of VENLAFAXINE HCL ER 150 MG CAP changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has declined 36.1%. It has been tracked across 308 weekly CMS publications since Nov 11, 2020.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 150 MG CAP?
Since Nov 11, 2020, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has ranged from a low of $0.1057 (Nov 20, 2024) to a high of $0.2086 (Aug 11, 2021), with a median of $0.1482 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 150 MG CAP?
9 manufacturers publish a NADAC-priced product with the same active ingredient and strength as VENLAFAXINE HCL ER 150 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures VENLAFAXINE HCL ER 150 MG CAP?
VENLAFAXINE HCL ER 150 MG CAP (NDC 31722000490) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.